查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
透明质酸□市场 - 增长、趋势和预测 (2023-2028)
市场调查报告书
商品编码
1273354

透明质酸□市场 - 增长、趋势和预测 (2023-2028)

Hyaluronidase Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 117 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

主要亮点

在预测期内，透明质酸□市场预计将以 8.5% 的复合年增长率增长

COVID-19 大流行对透明质酸□市场产生了重大影响。 例如，英国美容整形外科医生协会 (BAAPS) 2021 年的一篇文章称，前一年整容手术减少了 27%。 由于大多数整容手术都使用透明质酸□，可以说整容手术的减少减少了对透明质酸□的需求，从而影响了研究市场的增长。 然而，在目前的情况下，与大流行初期相比，由于 COVID-19 患者减少而恢復手术预计会增加对透明质酸□的需求。 因此，预计该市场在预测期内将出现显着增长。

随着越来越多的修復手术使用透明质酸□，以及越来越多的人想要微创美容治疗，所调查的市场正在增长。 例如，《美容整形外科》杂誌 2022 年 12 月的一篇文章指出，透明质酸□疗法可以纠正过度注射的填充剂，甚至可以溶解皮下结节。 皮肤科医生可以使用透明质酸□来纠正和逆转基于透明质酸的填充剂治疗失败的影响。 因此，由于这些优势，对透明质酸□的需求不断增加，从而推动了研究市场的增长。

随着越来越多的人想要不需要大量手术的美容治疗，市场也在不断增长。 例如，美国整形外科医师协会 (ASPS) 于 2022 年 2 月报告称，2020 年美国进行了 13,281,235 例微创整容手术。 肉毒桿菌毒素仍然是最受欢迎的手术，有 440 万，其次是软组织填充剂（340 万）和激光换肤（997,245）。 同一份文件还报告称，2020 年对男性和女性进行的微创整容手术总数分别为 820,123 例和 104,290,662 例。 因此，微创手术的引入增加了对透明质酸□的需求。

此外，2021 年，全球对整容手术的需求激增。 例如，意大利製药公司美纳里尼集团在 2021 年对印度 100 名皮肤科医生和整形外科医生进行的一项调查中，65% 的受访者表示，面部整形手术是印度最受欢迎的手术。同意这是整容，自全球 COVID-19 流行病开始以来，由于希望在社交媒体上看起来漂亮，37% 的受访者观察到整容手术的需求增加。 因此，人们对整容手术的认识不断提高，这增加了对透明质酸□的需求，从而推动了所研究市场的增长。

换句话说，随着透明质酸□越来越多地用于翻修手术以及人们希望微创整容手术，预计未来几年市场将显着增长。 然而，透明质酸□的不利影响也可能减缓所研究市场的增长。

透明质酸□市场趋势

动物来源的透明质酸□部分预计在预测期内将出现显着增长。

大多数已获批准和上市的透明质酸□品牌均来自动物。 这就是为什么动物来源的透明质酸□具有很高的市场份额。 牛和猪是一些最广泛使用的动物来源的透明质酸□。 Hydase (PrimaPharma)、Vitrase (Bausch & Lomb Incorporated) 和 Amphadase (Amphastar Pharmaceuticals, Inc) 是製造商生产的一些品牌。

此外，动物源性透明质酸□市场不断涌现出许多新产品，推动了该细分市场的增长。 例如，2021 年 8 月，Meso Esthetic 开始销售含有透明质酸的保湿液，可保持皮肤湿润。 这些发展正在推动这一领域的增长。

此外，动物透明质酸□优于合成类型这一事实似乎也促进了所研究细分市场的增长。 根据 NCBI 于 2021 年 4 月发表的一篇论文，美国每年进行超过 107,000 次皮肤填充手术。 因此，大量的皮肤填充手术将增加对动物源性透明质酸□的需求，这将导致该细分市场的增长。

因此，动物源性透明质酸□的优势以及大多数产品都含有动物源性透明质酸□这一事实正在推动这一细分市场的增长。

透明质酸□市场-IMG1

北美预计在预测期内将显着增长。

由于生产这些产品的大公司数量众多、进行高级治疗的人数众多以及开出这些治疗处方的皮肤科诊所数量众多，预计北美在全球透明质酸□市场中占有很大份额。 不断上升的医疗成本和改善的医疗基础设施也非常有利于扩大整个区域市场。

研究市场正在增长，因为越来越多的人正在接受整容手术。 例如，2022 年 1 月，美学协会宣布，到 2021 年，美国外科手术将增长 54%，非外科手术将增长 44%。 消息人士还表示，2021 年美国将进行 3,651,223 次神经毒素手术、1,857,339 次真皮填充术和 1,390,149 次皮肤治疗。 因此，可以说，在美国进行的大量非手术手术增加了对透明质酸的需求，推动了该地区研究市场的增长。

同样，美容整形外科杂誌 2021 年 9 月的一篇文章认为，乳房固定手术具有适应性，并且在墨西哥越来越受欢迎。 预计此类程序的增加将有助于未来几年市场的增长。

此外，2022 年 3 月，致力于改善严重自身免疫性疾病患者生活的全球免疫公司 Argenx SE 将推出针对全身性重症肌无力 (gMG) 的皮下治疗。(SC) Phase 报告了有利的顶线数据3 ADAPT-SC 试验测试 efgartigimod (1000mg efgartigimod-PH20)。 Argenx 已向 USFDA 提交了生物製品许可申请（ BLA ）。 因此，透明质酸□在治疗各种疾病中的应用正在推动该地区的市场增长。

因此，透明质酸□的大量应用和整容手术的盛行正在推动该地区研究市场的增长。

透明质酸□市场-IMG2

透明质酸□行业概况

透明质酸□市场竞争适中，由几家主要参与者组成。 目前主导市场的公司包括 PrimaPharma, Inc.、Amphastar Pharmaceuticals, Inc.、Bausch & Lomb Incorporated、Halozyme, Inc.、Sun Pharmaceutical Industries Ltd.、Stemcell Technologies, Inc.、The Cooper Companies, Inc. Ltd.、Valeant Pharmaceuticals 、CBC Pharma 和 Genomic Solutions。

其他福利：

  • Excel 格式的市场预测 (ME) 表
  • 3 个月的分析师支持

内容

第一章介绍

  • 调查假设和市场定义
  • 本次调查的范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动力
    • 扩大透明质酸□在矫正手术中的应用
    • 对微创美容治疗的需求不断增长
  • 市场製约因素
    • 与透明质酸□相关的副作用
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分

  • 按类型
    • 动物透明质酸□
    • 合成透明质酸□
  • 通过使用
    • 化疗
    • 体外受精
    • 眼科
    • 皮肤科
    • 其他用途
  • 地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东和非洲地区
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • PrimaPharma, Inc
    • Amphastar Pharmaceuticals, Inc.
    • Bausch & Lomb Incorporated
    • Halozyme, Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Stemcell Technologies, Inc.
    • The Cooper Companies, Inc.
    • Shreya Life Sciences Pvt. Ltd.
    • Valeant Pharmaceuticals
    • CBC Pharma
    • Genomic Solutions

第7章 市场机会与将来动向

简介目录
Product Code: 68684

Key Highlights

During the time frame of the forecast, the hyaluronidase market is expected to register a CAGR of 8.5%.

The COVID-19 pandemic had a significant impact on the hyaluronidase market. For instance, a 2021 article by the British Association of Aesthetic Plastic Surgeons (BAAPS) stated that there was a 27% decrease in cosmetic surgical procedures in the previous year.Since most of the aesthetic surgical procedures utilize hyaluronidase, a decrease in aesthetic surgical procedures decreased the demand for hyaluronidase and thereby impacted the growth of the studied market. However, in the current scenario, it is anticipated that the resumption of surgical procedures due to the reduction of COVID-19 cases may increase the demand for hyaluronidase compared to the beginning of the pandemic. Thus, the studied market is expected to witness significant growth over the forecast period.

The studied market is growing because more and more correction procedures are using hyaluronidase and more and more people want minimally invasive cosmetic treatments.For example, a December 2022 article in the journal Aesthetic Plastic Surgery said that hyaluronidase therapy can fix fillers that were injected too much and also help dissolve subcutaneous nodules.Dermatologists can use Hyaluronidase to correct and reverse the effects of failed hyaluronic acid-based filler treatments.Thus, due to these benefits, the demand for hyaluronidase is constantly increasing, thereby driving the growth of the studied market.

The market is also growing because more and more people want cosmetic treatments that don't require a lot of surgery.For example, the American Society of Plastic Surgeons (ASPS) reported in February 2022 that 13,281,235 minimally invasive cosmetic procedures were done in the United States in 2020. Botulinum toxin remained the most popular procedure with 4.4 million procedures, followed by soft tissue filler (3.4 million) and laser skin resurfacing (997,245).The source also reported that the total minimally invasive cosmetic procedures performed on males and females in 2020 were 820,123 and 10,429,962, respectively. Thus, the adoption of minimally invasive procedures is increasing the demand for hyaluronidase.

Furthermore, there has been a surge in demand for cosmetic procedures worldwide in 2021. For instance, a survey conducted in 2021 by the Menarini Group, an Italian pharmaceutical company, among 100 dermatologists and plastic surgeons across India revealed that 65% of the respondents agreed that a facelift is the most sought-after facial aesthetic procedure in India, and 37% of the respondents have observed an increased demand for aesthetic procedures since the onset of the global COVID-19 pandemic, with the desire to look good on social media. Thus, there has been a rise in awareness among people about aesthetic procedures, which is increasing the demand for hyaluronidase and thereby driving the growth of the studied market.

So, the market is expected to grow a lot over the next few years because hyaluronidase is being used more and more in corrective procedures and because people want less invasive cosmetic treatments. But the bad effects of hyaluronidase could slow the growth of the market that was studied.

Hyaluronidase Market Trends

Animal Derived Hyaluronidase Segment is Expected to Witness Significant Growth Over the Forecast Period.

Most of the approved and sold brands of hyaluronidase come from animal sources. This is why animal-based hyaluronidase has a high market share. Bovine and porcine are some of the most widely used animal sources. Hydase (PrimaPharma), Vitrase (Bausch & Lomb Incorporated), and Amphadase (Amphastar Pharmaceuticals, Inc.) are some of the brands manufactured by manufacturers.

Also, there have been a lot of new products on the animal-derived hyaluronidase market, which has helped this segment grow.For example, in August 2021, Mesoestectic started selling a line of moisturizing solutions that contain hyaluronic acid to keep the skin hydrated.Thus, such developments are driving the growth of this segment.

Also, the fact that animal-based hyaluronidase is better than synthetic types is likely to help the studied segment grow. In the United States, more than 107,000 dermal filler surgeries are done each year, according to an article published by the NCBI in April 2021. So, a high number of dermal filler surgeries are likely to increase the need for hyaluronidase from animals, which will help this segment grow.

Therefore, the advantages of animal-based hyaluronidase and the fact that the majority of products contain animal-based hyaluronidase are driving this segment's growth.

Hyaluronidase Market - IMG1

North America is Expected to Witness Significant Growth Over the Forecast Period.

North America is expected to have a big share of the global hyaluronidase market because it has a lot of big companies that make these products, a lot of people who use advanced treatments, and a lot of dermatology clinics that prescribe these treatments. The fact that healthcare costs are rising and there is a well-established healthcare infrastructure is also very beneficial to the expansion of the regional market as a whole.

The study market is growing because more and more people are getting cosmetic surgery.For example, the Aesthetic Society said in January 2022 that in the United States, surgical procedures went up by 54% and non-surgical procedures went up by 44% in 2021. The source also said that in the United States in 2021, there would be 3,651,223 neurotoxin procedures, 1,857,339 dermal filler procedures, and 1,390,149 skin treatment procedures.So, the high number of non-surgical procedures done in the United States is increasing the demand for hyaluronidase and driving the growth of the studied market in the region.

In a similar vein, an article by Aesthetic Plastic Surgery from September 2021 claimed that mastopexy procedures were adaptable and increasing in popularity in Mexico.During the next few years, the increase in these kinds of procedures is likely to help the market grow.

Also in March 2022, Argenx SE, a global immunology company that works to improve the lives of people with severe autoimmune diseases, reported positive topline data from the Phase 3 ADAPT-SC study testing subcutaneous (SC) efgartigimod (1000 mg efgartigimod-PH20) as a treatment for generalized myasthenia gravis (gMG).Argenx submitted a biologics license application (BLA) to the USFDA. Thus, such applications of hyaluronidase in the treatment of various diseases are driving the growth of the market in the region.

As a result, the numerous applications for hyaluronidase and the prevalence of cosmetic procedures are driving the growth of the studied market in the area.

Hyaluronidase Market - IMG2

Hyaluronidase Industry Overview

The hyaluronidase market is moderately competitive and consists of a few major players. Some of the companies that are currently dominating the market are PrimaPharma, Inc., Amphastar Pharmaceuticals, Inc., Bausch & Lomb Incorporated, Halozyme, Inc., Sun Pharmaceutical Industries Ltd., Stemcell Technologies, Inc., The Cooper Companies, Inc., Shreya Life Sciences Pvt. Ltd., Valeant Pharmaceuticals, CBC Pharma, and Genomic Solutions.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Penetration of Hyaluronidase in Correction Procedures
    • 4.2.2 Rising Demand for Minimally Invasive Aesthetic Treatments
  • 4.3 Market Restraints
    • 4.3.1 Adverse Effects Associated With Hyaluronidases
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Type
    • 5.1.1 Animal-Derived Hyaluronidase
    • 5.1.2 Synthetic Hyaluronidase
  • 5.2 By Application
    • 5.2.1 Chemotherapy
    • 5.2.2 In Vitro Fertilization
    • 5.2.3 Ophthalmology
    • 5.2.4 Dermatology
    • 5.2.5 Others Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 PrimaPharma, Inc
    • 6.1.2 Amphastar Pharmaceuticals, Inc.
    • 6.1.3 Bausch & Lomb Incorporated
    • 6.1.4 Halozyme, Inc.
    • 6.1.5 Sun Pharmaceutical Industries Ltd.
    • 6.1.6 Stemcell Technologies, Inc.
    • 6.1.7 The Cooper Companies, Inc.
    • 6.1.8 Shreya Life Sciences Pvt. Ltd.
    • 6.1.9 Valeant Pharmaceuticals
    • 6.1.10 CBC Pharma
    • 6.1.11 Genomic Solutions

7 MARKET OPPORTUNITIES AND FUTURE TRENDS